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Abstract: Ticks are the most important vectors of pathogens affecting both domestic and wild animals
worldwide. Hard tick feeding is a slow process—taking up to several days—and necessitates extended
control over the host response. The success of the feeding process depends upon injection of tick
saliva, which not only controls host hemostasis and wound healing, but also subverts the host
immune response to avoid tick rejection that creates a favorable niche for the survival and propagation
of diverse tick-borne pathogens. Here, we report on the molecular and biochemical features and
functions of an Ixodes ricinus serine protease inhibitor (IrSPI). We characterize IrSPI as a Kunitz
elastase inhibitor that is overexpressed in several tick organs—especially salivary glands—during
blood-feeding. We also demonstrated that when IrSPI is injected into the host through saliva, it had
no impact on tissue factor pathway-induced coagulation, fibrinolysis, endothelial cell angiogenesis
or apoptosis, but the protein exhibits immunomodulatory activity. In particular, IrSPI represses
proliferation of CD4+ T lymphocytes and proinflammatory cytokine secretion from both splenocytes
and macrophages. Our study contributes valuable knowledge to tick-host interactions and provides
insights that could be further exploited to design anti-tick vaccines targeting this immunomodulator
implicated in I. ricinus feeding.
Keywords: Ixodes ricinus; tick–host–pathogen interactions; anti-tick vaccine; serine protease inhibitor;
immunomodulator; macrophages; lymphocytes
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1. Introduction
Ticks are obligate hematophagous arthropods able to feed on diverse vertebrate hosts including
mammals, birds, amphibians, and reptiles. They cause substantial economic losses in the livestock
industry due to blood spoiling and secondary infection of bite wounds, which consequently decrease
food production and the value of leather. Crucially, ticks are excellent vectors for pathogens, including
bacteria, parasites, and viruses. They are—after mosquitoes—the second-most common vector of
human pathogens and the first for animal health [1]. In particular, the hard tick Ixodes ricinus is the
most widespread and abundant tick species in Europe, as well as the most efficient transmitter of
pathogens that significantly impact both human and animal health [2]. This tick species follows a
three-host life cycle where each of the three distinct life stages (larvae, nymph and adult) feeds only
once on its respective host.
The hard tick blood meal’ is one of the most extended processes of all blood-feeding arthropods.
Several hard tick species feed over ten days as adults, thus, causing severe host tissue damage.
The success of the blood meal is critically dependent on saliva, which represents the primary tick-host
interface (reviewed in [3]). Indeed, tick saliva possesses several essential properties that facilitate
feeding, including an ability to repress host pain at the tick bite site, thus, preventing early detection
by the host. Besides, tick saliva can counteract host hemostatic and immunological responses at the
site of injury. Ticks are pool-feeders, meaning that they create a hemorrhagic blood pool by alternating
blood absorption and saliva injection. As such, the saliva’s anti-coagulant properties maintain the
blood pool in a fluid state by blocking blood coagulation cascade activation and promoting fibrinolysis.
Moreover, tick saliva impedes the host’s innate immune system, by preventing complement activation
and immune cell recruitment, thus, precluding tissue remodeling and angiogenesis, as well as local
inflammation. Tick saliva also impairs anti-tick adaptive immune responses, by repressing lymphocyte
recruitment at the tick bite site. Finally, these tick bite-associated processes create an environment
favoring the transmission of tick-borne pathogens (TBP) to the host.
A better understanding of tick-host-pathogen interactions is central to the development of
improved tick and tick-borne disease (TBD) control methods [4]. In order to identify tick factors
involved in both tick biology and pathogen transmission, we used next-generation sequencing (NGS) to
compare gene expression in salivary gland (SG) tissue from uninfected and Bartonella henselae-infected
I. ricinus ticks [5]. This gram-negative bacterium is responsible for cat scratch disease in humans and is
transmitted from cat to cat by fleas. Although the majority of human cases are due to scratches and
bites from infected cats, we have previously demonstrated that I. ricinus can also directly transmit this
pathogen [6]. A small percentage of tick genes (5.6%) were found to be modulated by this bacterial
infection. The most overexpressed gene—that we named Ixodes ricinus serine protease inhibitor
(IrSPI)—encoded a putative serine protease inhibitor. Preliminary RNA interference (RNAi) functional
analysis revealed that IrSPI is implicated in tick feeding, as well as in B. henselae infection of tick SG,
rendering it a promising target as an anti-I. ricinus vaccine. It is also known that several serine protease
inhibitors (SPI) are involved in the aforementioned tick saliva processes that maintain blood pools,
further justifying our interest in IrSPI [7]. Serine protease inhibitors are one of the leading protein
families injected into the host by ticks during blood-feeding, as inhibited proteins play key roles in
regulating host coagulation, angiogenesis, hemostasis, and immune responses. Moreover, in ticks,
several serine protease inhibitors are involved in blood digestion, the tick’s innate immune system,
tick reproduction, as well as pathogen transmission [7].
In this study, we elucidate the IrSPI role both in tick biology and at the interface of the tick and the
vertebrate host during feeding. In silico characterization of IrSPI confirmed that it belongs to the Kunitz
type I family of serine protease inhibitors. We showed that IrSPI is induced during blood-feeding
and that the protein is probably injected into the host, suggesting involvement in modulating host
responses to tick feeding. We observe that the elastase is inhibited by recombinant IrSPI, whereas,
neither the tissue factor pathway blood coagulation, the fibrinolysis, the endothelial cell apoptosis nor
the angiogenesis is affected. Finally, we demonstrate that IrSPI modulates the host immune response
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by reducing the proliferative capacity of T lymphocytes and by altering the cytokine expression profile
of both macrophages and splenocytes.
2. Material and Methods
2.1. Ethics
This study was carried out in strict accordance with good animal care practices recommended
by the European guidelines. The local ethics committee approved animal experiments involving
rabbits and mice used for tick feeding for animal experimentation (ComEth Anses/ENVA/UPEC;
Permit Number 2015091413472401). Rabbits used for feeding pathogen-free ticks have been put up for
adoption via the White Rabbit Association, Paris, France.
2.2. Ticks
This study used I. ricinus ticks either collected from the field, or from a pathogen-free colony.
Questing ticks (nymphs and adults) were collected by flagging in the Sénart forest, located south-east
of Paris (France), as previously described [8]. All pathogen-free I. ricinus ticks were derived from a
laboratory colony reared at 22 ◦C in 95% relative humidity, with 12 h light/dark cycles as previously
described [9].
2.3. Cloning and Sequencing of IrSPI cDNA
Following NGS of the I. ricinus salivary gland transcriptome, we had previously generated a
total of 24,539 isotigs [5]. Of these, the IrSPI coding sequence (GenBank KF531922.2) without the stop
codon (282 bp) was amplified with primers ID23822F (5′-ACATCTACCGTTCAAGATGAAG -3′) and
ID23822R (5′-TCTAAGTGCCTTGCAGTAGTC-3′), and then cloned into the pET28 vector following
the manufacturer’s instructions (Novagen, Merck KGaA, Darmstadt, Germany). After transformation
of Escherichia coli TOP10 bacteria (ThermoFisher Scientific, Waltham, MA, USA) using plasmid and
kanamycin selection, correct IrSPI sequence insertion was validated by PCR and sequencing.
2.4. Recombinant IrSPI Protein Production
The open reading frame (ORF) of IrSPI lacking the 5′ sequence encoding its signal peptide
(MKATLVAICFFAAVSYSMG) was synthetized (Eurofins Scientific, Luxembourg) as a fusion
protein with sequences encoding Twin-Strep-Tag (WSHPQFEKGGGSGGGSGGGSWSHPQFEK) and
enterokinase (DDDDDK). The BglII and EcoRI restriction sites were used to insert the sequence into
the pMT/BIP/V5-His plasmid (ThermoFisher, Waltham, MA, USA). The recombinant IrSPI protein
was produced by the Recombinant Proteins in Eukaryotic Cells Platform, Pasteur Institute, Paris,
France. Briefly, Drosophila S2 cells (Invitrogen, Carlsbad, CA, USA) adapted to serum-free Insect
Xpress (Lonza, Basel, Switzerland) medium were co-transfected with pMT/BIP/IrSPI and the pCoPURO
vector (Addgene, Cambridge, MA, USA) conferring resistance to puromycin, using the cellfectin II
transfection reagent (Invitrogen, Carlsbad, CA, USA). The upstream pMT/BiP/V5-His Drosophila BiP
secretion signal enables the recombinant protein to enter the S2 cell secretory pathway for recovery in
the culture medium. IrSPI expression was driven by the metallothionein promoter after induction
by 5 µM CdCl2. Clarified cell supernatants were concentrated 10-fold using Kicklab tangential flow
filtration cassettes (cut-off 10 kDa, GE Healthcare, Chicago, IL, USA) and adjusted to pH 8.0 in 10 mM
Tris before purification in an AKTA Avant system by Steptrap-HP chromatography (GE Healthcare).
Final purification was achieved by gel filtration using a Superdex 75 HiLoad 16/60 column (GE
Healthcare) equilibrated in phosphate buffered saline without Ca2+ and Mg2+ (PBS-X). Protein quantity
was estimated by peak integration.
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2.5. IrSPI Refolding
Eight µg of IrSPI were refolded for 30 min at 25 ◦C in a final volume of 100 µL containing
10 µg of the disulfide isomerase protein (Sigma-Aldrich, St. Louis, MO, USA) with reduced/oxidized
glutathione (Sigma-Aldrich) (2 mM/0.2 mM) in borate buffer (100 mM Borate, 150 mM NaCl, pH 7.4).
2.6. Circular Dichroism
Circular dichroism experiments were performed in the far-UV region using an Aviv CD 215
model spectrometer equipped with a water-cooled Peltier unit. A 200 µL volume of recombinant
IrSPI at 0.075 µg/µL was used to record spectra in a cell with a 1-mm path length in the far-UV range
(between 190 to 270 nm) at 25 ◦C. IrSPI and its cognate buffer were successively screened ten times to
produce an averaged spectrum. The spectra were corrected using buffer baselines measured under the
same conditions. Data were normalized to residue molar absorption measured in mdeg (M−1 cm−1)
and expressed as delta epsilon (∆ε) enabling the BestSel website algorithm to analyze for secondary
structure predictions [10].
2.7. Analytical Ultracentrifugation (AUC)—Sedimentation Velocity Experiment
The oligomerization state of IrSPI was determined with a sedimentation velocity experiment in a
ProteomeLab XL-I analytical ultracentrifuge (Beckman-Coulter, Brea, CA, USA). Briefly, after loading
IrSPI at 0.075 mg.ml−1 in a 1.2 cm epoxy double-sector cell, the cell assembly was equilibrated for 1.5 h
at 20 ◦C in a four-hole AN60-Ti rotor. The sample was spun at 42,000 rpm for 10 h, and 400 scans for
both Rayleigh interference and absorbance at 280 nm were recorded. Absorbance data were collected
at a constant radial step size of 0.001 cm. Partial specific volume of 0.70 and the extinction coefficient
ε at 280 nm of 14,350 L.mol−1.cm−1 were theoretically calculated at 20 ◦C from the IrSPI amino acid
sequence using Sednterp software (Spin Analytical, Berwick, ME, USA).
PBS-X density ρ and viscosity η at 1.0053 g.mL−1 and 1.018 cP, respectively, were also determined
with Sednterp at 20 ◦C. The sedimentation profile of IrSPI was analyzed in SEDFIT using the continuous
size distribution c(s) model [11].
2.8. MALDI-TOF/TOF Analysis
Recombinant IrSPI protein purity and integrity were confirmed using a Bruker UltrafeXtreme
MALDI-TOF/TOF instrument (Bruker-Daltonics, Germany). Briefly, 1 µL of protein at 0.075 mg/mL
was deposited on an MTP 384 ground steel target plate with 1 µL of 2,5-dihydroxybenzoic acid
(2,5-DHB) in 50% acetonitrile, 0.1% trifluoroacetic acid as matrix solution. Data were acquired using
Flexcontrol software (Bruker-Daltonics, Germany) and shots were recorded in positive ion linear
mode. Mass spectra were externally calibrated in the m/z range of 5–20 kDa with a protein calibration
standard (Bruker-Daltonics, Germany) and analyzed with the Flexanalysis software (Bruker-Daltonics,
Germany).
2.9. Serine Protease Inhibition Assays
Serine protease inhibition assays were performed at 37 ◦C by using a thermostated Multiskan
GO ELISA plate reader (Thermo Scientific). Serine proteases and their corresponding substrates (in
brackets) were purchased from Sigma Aldrich and, serine proteases were used with the following
concentrations—24.6 nM Trypsin-T1426 (N-Benzoyl-Phe-Val-Arg-p-nitroanilide hydrochloride),
46.5 nM Chymotrypsin-C3142 (N-Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide), 21.6 nM Elastase-45125
(N-Succinyl-Ala-Ala-Ala-p-nitroanilide), 43 nM Thrombin-T6884 (Sar-Pro-Arg-p-nitroanilide
dihydrochloride), and 33 nM Kallikrein-K3627 (N-Benzoyl-Pro-Phe-Arg-p-nitroanilide hydrochloride).
Reactions were performed in 20 mM Tris-HCl, 150 mM NaCl, 0.1% BSA, pH 7.4 buffer (except for
thrombin inhibition assay performed at pH 6.5), with a final substrate concentration of 0.2 mM.
All reactions were performed with both non-refolded and refolded recombinant IrSPI in the refolding
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buffer, this last buffer being used as a negative control for this latter condition. After initial incubation
of serine protease with or without recombinant protein for 15 min at 37 ◦C, the A405 was recorded for
30 min (every 10 s) at the same temperature. Initial slopes of substrate hydrolysis together with their
correlation coefficients, were obtained by linear regression analysis using GraphPad Prism software
(San Diego, CA, USA). Results were expressed as the percentage inhibition in the presence of IrSPI
taking into account the effect of the refolding buffer alone on the enzyme activity.
2.10. Ticks Infected with Tick-Borne Pathogens
B. birtlesii-infected nymphs pre-fed for three days on mice were obtained from molted larvae
infected on mice injected with an in vitro B. birtlesii (IBS325T) culture as previously described [12].
B. henselae-infected females pre-fed for four days were obtained with the previously described membrane
feeding system and following the same protocol [5]. B. henselae and B. birtlesii infection in ticks was
confirmed by RT-PCR using primers described by Reis and co-workers [12].
2.10.1. Tick Infection with Escherichia coli
E. coli (CIP7624 strain, Pasteur Institute, Paris) was cultivated at 37 ◦C under atmospheric
conditions for one night on Luria Bertani (LB)-agar plates and then for 24 h in liquid LB medium.
Bacterial concentration was then evaluated by spectrophotometry at 600 nm (OD at 1 represents
2.2 × 109 CFU/mL). Three pathogen-free I. ricinus females were nano-injected with 250 nL (1× 107 CFU)
of bacterial suspension into the body cavity using a glass microcapillary attached to a nanoinjector
pump (Drummond, Broomall, PA, USA) driven by a Micro 4 controller (World Precise Instruments,
Sarasota, FL, USA). Three other females injected with 250 µL of PBS and three un-injected ticks were
used as controls. E. coli infection was confirmed by qPCR with primers targeting the WecA gene [13].
2.10.2. Tick Saliva and Tick Organ Collection
For saliva collection, 34 female I. ricinus from the field were pre-fed for five days on a rabbit as
previously described [14]. After detachment, ticks were then physically immobilized on microscopy
slides with the hypostome positioned in sterile 10 µL tips. After applying 5 µL 5% pilocarpine in
methanol to the tick dorsum, ticks were positioned upside down to facilitate collection of saliva
and placed in dark, humid chambers as described by Patton et al. [15]. After about 5 h, a pool of
approximately 50 µL of saliva was obtained (average of 1.5 µL per tick) and stored at −80 ◦C until use.
After the saliva collection, salivary gland extracts were prepared. Salivary glands were collected
from 17 ticks by dissection under a magnifying glass. Glands were pooled and immediately rinsed three
times in cold-PBS (137 mM NaCl, 1.45 mM NaH2PO4.H2O, 20.5 mM Na2HPO4, pH 7.2). They were
then sonicated (Bandelin HD 2070, equipped with the MS 72 probe) three times for 15 s in 1.5 mL of
PBS on ice, at 37% power, before concentration to a final volume of 100 µL with the Amicon Ultra
filters (3 kDa threshold) and stored at −80 ◦C until use in western blot. The remaining 17 ticks were
then dissected under a magnifying glass, and salivary glands, midgut, ovaries, synganglion and finally
the rest of tick body (carcasse) were isolated, rinsed three times in cold-PBS, pooled according to organ
and stored at −80 ◦C until RNA extraction.
2.10.3. Total RNA Extraction
To evaluate gene expression, RNA extraction was performed on eggs, whole unfed larvae,
nymphs, adult males and females, fed nymphs from the tick colony, and on tick organs from pre-fed
field-collected females using the Nucleo Spin RNA (Macherey-Nagel GmbH & Co. KG, Düren,
Germany) kit according to the manufacturer’s instructions. Tissue homogenization was first achieved
with Precellys24 (Bertin instruments, Montigny-le-Bretonneux, France) in a lysis buffer containing
β-mercaptoethanol with silicate beads for organs and metal beads (2.8 mm of diameter) for whole ticks
and eggs. RNA was eluted in 30 µL RNAse free water and RNA concentration was determined by
measuring absorbance at 260 nm using a Nanodrop one (Thermo Fisher Scientific).
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2.10.4. Quantitative RT-PCR
To evaluate IrSPI expression at different tick life stages, RNA samples from one egg deposition,
120 unfed larvae, 20 unfed nymphs, five unfed males, and five unfed females from the tick colony
were used. The temporal expression profile of IrSPI during feeding was evaluated in RNA samples
from 20 unfed, 20 three-day, and 20 five-day fed nymphs from the colony after feeding on rabbits as
previously described [14]. To evaluate IrSPI expression in different tick organs, pooled RNA samples
from salivary glands, midgut, synganglion, ovaries, and carcasses of 17 females from the field that
were pre-fed for five days on rabbits were used. Finally, the impact of tick infection with either
transmitted or untransmitted bacteria was evaluated. For B. birtlesii, pooled salivary gland, gut, and
ovary samples from eight infected nymphs pre-fed for three days were used, while the same organs
from four uninfected ticks were used as control. For B. henselae, pooled salivary glands (13), guts (14),
and ovarian tissues (16) from infected females and non-infected controls pre-fed for four days were
used. Finally, pooled RNA samples from three E. coli-infected females from the colony were analyzed
alongside three PBS-injected ticks or three uninjected ticks as controls.
Reverse transcription was performed with SuperScript III (Invitrogen) with 100 to 400 ng RNA
per reaction. First-strand cDNA synthesis was performed by using 2.5 µM Oligo dT primers in a total
volume of 20 µL at 65 ◦C for 5 min, 4 ◦C for 3 min, 50 ◦C for 50 min, and 70 ◦C for 15 min. Following
RNase H treatment (Invitrogen) at 37 ◦C for 20 min, expression of IrSPI, WecA (E. coli), defensin 6, and
rps4 (a tick housekeeping gene) was evaluated by qPCR using the LightCycler 480 System (Roche,
Basel, Switzerland). The SyBr green Master mix (Roche) added to 2 µL of cDNA, contained 6 µL of SyBr
green vial 2, and 0.5 µM of both forward and reverse primers in a total volume of 12 µL. Previously
described primers were used to detect IrSPI transcripts [5], while for defensin-6, primers were designed
according to the sequence published by Tonk et al. [16]: (F: 5′-TCGTCGTGATGATTGCGGGT-3′ and R:
5′-TCGTCGTGATGATTGCGGGT-3′). The following qPCR cycle conditions were used: 95 ◦C 5 min;
95 ◦C 10 s, 60 ◦C 15 s, 72 ◦C 15 s, for 45 cycles. Each sample was amplified in triplicate and results were
analyzed with Roche LightCycler 480 Software V1.5.0. Relative quantification of gene expression was
calculated using the comparative Cp method [17]. IrSPI Cp was then normalized using the I. ricinus
rps4 gene [18], and expressed as fold change after ∆∆Cp analysis. Analysis of IrSPI expression in wild
female organs was performed using a plasmid containing IrSPI cDNA as a positive control, and IrSPI
quantity was expressed as IrSPI cDNA copy number.
2.10.5. In Situ Hybridization
In situ hybridization was performed as previously described [19]. Briefly, a 183-nucleotide
long single-stranded DNA probe containing digoxygenin dNTP was prepared via asymmetric PCR
(Roche Molecular Biochemicals) and the following primers: 5′-TGACTGAGACACAATGCAGA -3′
(forward) and 5′-TTCCGTACGGACATTCCCGC -3′ (reverse). The salivary glands from partially fed
pathogen-free I. ricinus females engorged for eight days by means of a membrane feeding system [9]
were dissected in ice-cold PBS and subsequently fixed in 4% paraformaldehyde (Sigma-Aldrich P6148)
for 2 h at room temperature. After three washes in PBST (PBS + 0.2% Triton), the tissues were treated
with 25 µg/mL proteinase K for 10 min at RT. The reaction was stopped by adding PBST-glycine (0.2%
of triton and 2 mg/mL glycine) for 5 min. Samples were re-fixed in 4% paraformaldehyde at RT and
washed in PBST three times for 5 min. Hybridization was performed with either sense or antisense
probe diluted ten times in hybridization solution (HS; 50% formamide, 5x Saline Sodium Citrate
solution (SSC), 50 g/mL heparin, 0.1% Tween 20, and 100 g/mL salmon sperm DNA). The samples were
then incubated in HS containing the representative probe for 30 h at 48 ◦C in a humidified chamber.
After hybridization, tissues were washed sequentially in HS (12 h, 48 ◦C), HS-PBST (1:1; 5 min, RT) and
PBST (5 min, RT). After blocking in 1% BSA in PBST for 20–30 min at RT, the tissues were immediately
incubated with sheep anti-digoxigenin-AP (alkaline phosphatase; Roche Diagnostics, Germany) at a
dilution of 1:1000 in PBST overnight at 4 ◦C. Tissues were washed three times with PBST. Colorimetric
reactions were developed by incubation with staining solution made from NBT/BCIP Ready-to-Use
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Tablets (Roche) according to the manufacturer’s protocol. Salivary glands were mounted in glycerol
and examined under an optical microscope (Olympus BX53, Waltham, MA, USA). Digital captured
images were assembled and enhanced in Adobe Photoshop CS4.
2.10.6. Anti-IrSPI Serum Production
Anti-IrSPI sera were produced against both the endogenous protein following tick bites in rabbits
and the recombinant protein in mice. Two hundred nymphs and around 2000 larvae from our I. ricinus
colony were fed on one New Zealand white rabbit (Charles River) until feeding completion (seven
days) as previously described [14]. At day 17 post-infestation, the rabbit was sacrificed, and blood
recovered by cardiac puncture. Five BALB/c mice were used to produce antibodies against IrSPI over a
90-day protocol. Three subcutaneous vaccinations (Days 0, 14, and 28) of 10 µg recombinant IrSPI
were performed. Blood samples were collected retro-orbitally at 0, 14, 28, 42, and 56 days after the
primary injection, and through final cardiac puncture on day 90. Blood from both mice and rabbits
was stored at RT for 2 h before two-step centrifugation at 6500× g for 5 min to obtain a clear serum that
was stored at −20 ◦C until used. Recombinant protein immunogenicity and anti-IrSPI murine antibody
affinity were confirmed through ELISA experiments.
2.10.7. Western Blot Analysis
A volume of 10 µL of both saliva and salivary gland extracts, as well as 1.5 µg of recombinant
IrSPI protein as positive control, were analyzed on 4–15% acrylamide gels under reducing conditions
(Mini protean TGX stain-free gels, Bio-Rad, Hercules, CA, USA) followed by UV detection (ChemiDoc,
Bio-Rad, Hercules, CA, USA), or were immunoblotted with sera from mice or rabbits after IrSPI
immunization or tick infestation, respectively. Transfer to nitrocellulose membranes was performed
using the transblot turbo (Bio-Rad) followed by saturation in TBS-5% milk for 1 h at RT and incubation
for 1 h at RT with primary antibodies diluted in TBS-5% milk (1/1000 dilution for mice immune serum
and 1/100 for rabbit serum). After three washes in TBS-5% milk, antibody binding was detected with
the BCIP/NBT Color development system (Roche), using either anti-mouse or anti-rabbit alkaline
phosphatase-conjugated antibodies (A3562 or A3687, respectively; Sigma-Aldrich) diluted 1:7500 in
TBS-5%. Results were analyzed with the ChemiDoc instrument (Bio-Rad) and the accompanying
ImageLab 1.5 software (Bio-Rad).
2.10.8. Thrombin Generation, Clot Waveform, and Fibrinolysis Assays
Thrombin generation assays (TGA) were adapted from the calibrated automated thrombogram
(CAT) as described by Jourdi et al. [20]. Briefly, 80 µL calibrated platelet-poor plasma (PPP,
Cryopep, Montpellier, France) with or without 0.8 µM refolded IrSPI, and 20 µL PPP-Reagent
(Stago, Asnières–sur-Seine, France) were dispensed into wells of flat-bottomed microtiter plates. After
5 min of preheating at 37 ◦C, thrombin generation was initiated by automated injection of 20 µL of
a substrate solution and calcium mixture (FluCa, Stago, Asnières–sur-Seine, France). Progress of
Z-Gly-Gly-Arg-7-amino-4-methylcoumarin hydrolysis was recorded every 10 s by a thermostated
Tecan Infinite M200 Pro (excitation 340 nm, emission 440 nm). Fluorescence measurements were
analyzed using GraphPad Prism software. Lag time, time to peak (TTP), the maximum amount of
thrombin formed (peak height), and endogenous thrombin potential (ETP) were computed using the
area under the curve method. Clot waveform assays were simultaneously performed by utilizing
the Tecan reader’s capacity to simultaneously record fluorescence and A405 as described by Jourdi
et al. [21]. Data were analyzed using GraphPad Prism software to estimate the lag time of clot formation,
defined as the time needed to reach 15% of maximum turbidity. Fibrinolysis was measured by the clot
waveform assay except that 6 nM of tPA (Actilyse, Boehringer Ingelheim, Germany) was added to
the PPP prior to triggering clot formation. Time to half-lysis was defined as the time needed to halve
the maximum turbidity. Obtained results were then compared between positive controls, negative
controls (refolding buffer), and samples treated with IrSPI.
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2.10.9. IrSPI Impact on Endothelial Cell Apoptosis
The mature human skin microvascular endothelial cell line (HSkMEC) [22], was cultivated in
24-well plates in complete OptiMEM® medium (OptiMEM® with 2% Fetal Bovine Serum, 0.5 µg/mL
fungizone, and 40 µg/mL gentamicin, Gibco). After 24 h, the medium was replaced by 1 µM of
recombinant IrSPI that had been refolded or not, or by their cognate controls, that is, refolding buffer
or complete OptiMEM® medium, respectively. Cells were then incubated for 40 h at 37 ◦C. At 24 h,
staurosporin (1 µM) was added to the corresponding wells as a positive apoptosis control. Cells were
detached by trypsinization, washed, labeled with Annexin-V-FITC and propidium iodide according
to the manufacturer’s instructions (FITC Annexin V kit and Dead Cell Apoptosis Kit, Invitrogen),
and analyzed by cytofluorimetry with the LSR Fortessa X20 instrument (Becton Dickinson, Franklin
lakes, NJ, USA).
2.10.10. IrSPI Impact on Host Angiogenesis
The potential cytotoxicity of IrSPI was initially evaluated on HSkMEC cells. After 24 h of culture
in 96-well plates in complete OptiMEM® medium, the medium was replaced by refolded or untreated
IrSPI at 2, 1, 0.5, 0.25, 0.125, or 0.0625 µM, or by the corresponding controls; namely, refolding
buffer or complete OptiMEM® medium. After 48 h of culture, each supernatant was removed and
replaced by a solution of Alamar BlueTM (100 µL, at 1/22 dilution in OptiMEM® medium, Invitrogen).
Cell toxicity was assessed after 3 h of incubation by measuring fluorescence intensity using the Victor
3 V spectrofluorometric multiwell plate reader (Perkin Elmer, Waltham, MA, USA; excitation at
560 nm; emission at 605 nm). The ability of IrSPI, refolded or not, to modulate host angiogenesis was
then evaluated on two human endothelial cell lines, HSkMEC and HEPC-CB1 (human endothelial
progenitor cells-cord blood 1), a human progenitor endothelial cell line [23]. To coat plates, 50 µL
of MatrigelTM (50% dilution in OptiMEM® medium) was dispensed into 96-well microplates and
incubated for 30 min at 37 ◦C to allow MatrigelTM polymerization. Cells (1.5 × 105 cells/mL) were
resuspended in 100 µL OptiMEM® containing either 1 or 0.5 µM of the recombinant protein, refolded
or not, or, as controls, the refolding buffer or culture medium, and were then seeded into the MatrigelTM
matrix-containing wells. Plates were incubated in a videomicroscope chamber at 37 ◦C with 5%
CO2. Pseudo vessel formation was visualized for 9.5 h with an inverted microscope equipped with a
CCD camera (Axio Observer Z1, Zeiss, Le Pecq, France), with acquisitions every 30 min via the Zen
software (Zeiss, Oberkochen, Germany). Angiogenesis was quantified with the ImageJ software (with
Angiogenesis Analyzer) according to several parameters: Number of segments and length, number of
meshes, and number of junctions [24].
2.10.11. Splenocyte Proliferation Assay
Spleens of three OF1 mice (8 weeks of age) were gently crushed in individual cell strainers
(100 µm). After 2 washes in complete medium (RPMI 1640 (Gibco) with 5% sodium pyruvate,
1% penicillin/streptomycin (Invitrogen), 1% 200 mM L-glutamine (Gibco), and 10% heat-inactivated
FCS (Invitrogen), cells were centrifuged for 5 min at 1400 rpm and incubated at 37 ◦C for 2 min in sterile
RBC lysis solution (Invitrogen). Lysis was arrested by adding 30 mL PBS, and cells were pelleted and
resuspended in 2 mL complete medium. Cells were then labeled with Carboxy fluorescein succinimidyl
ester (CFSE) (10 µM, Molecular Probes) for 5 min at RT in the dark, and quenched by adding five
volumes of complete cold medium. CFSE-labeled cells were maintained on ice for 5 min and then
washed twice in complete medium. The proliferation of mitogen-stimulated cells was then measured
in the presence or absence of IrSPI, in triplicate wells for each condition. For each mouse, CFSE-labeled
cells (5 × 105 per well in 50 µL) were dispensed in 96-well U-bottomed plates. Recombinant IrSPI (2 µg
per well in 50 µL complete medium) or medium alone was added and cells were incubated at 37 ◦C in
5% CO2 for 2 h. Concanavalin A (ConA) (2 µg/mL in 100 µL of complete medium containing 0.1 mM
ß-mercaptoethanol) was then added. Single wells containing CFSE- labeled and unlabeled cells were
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included for isotype controls and for spectral compensation for CFSE and the viability label. After
three days of culture (37 ◦C in 5% CO2), supernatants (150 µL/well) were collected and stored at −80 ◦C
for subsequent analysis of cytokine expression and cells were harvested for phenotypic labeling and
flow cytometry.
For phenotypic labeling, all antibodies were purchased from eBiosciences and diluted in PBS
containing 0.5% bovine serum albumin and 2 mM EDTA (PBS–BSA–EDTA). To block Fc receptors,
cells were resuspended in 50 µL of anti-mouse-CD16/32 (0.5 µg/well) and incubated for 15 min at 4 ◦C.
Cells were then resuspended in a cocktail of PE-anti-CD4 and APC-anti-CD8 (both at 0.125 µg/well)
and eFluor 450-anti-CD19 and APC-eFluor 780-anti-CD3e (both at 0.5 µg/well). For isotypic controls,
the same concentration of the cognate isotypic antibodies was used. After 30 min, cells were washed
and labeled for 30 min with a viability marker (LIVE⁄DEAD® Fixable Aqua Dead Cell Stain Kit,
Molecular Probes, Eugene, OR, USA) according to the manufacturer’s recommendations. Cells were
washed and fixed with 150 µL of 1% paraformaldehyde in PBS. Flow cytometry was performed using
the FACSCanto II cytometer (BD Biosciences, San Jose, CA, USA). Data were acquired and analyzed
with FACSDiva (BD Biosciences, San Jose, CA, USA) and FlowJo software (Tree Star, Ashland, OR,
USA), respectively. Live cells, distinguished by referring to dot plots of Aqua staining versus side
scatter, were gated as B or T lymphocytes on the basis of CD19 or CD3e staining, respectively, and T
cells were further distinguished for CD4 or CD8 expression. The CFSE staining of each subset was
then examined.
2.10.12. Macrophage Stimulation Assay
Macrophages were isolated from the bone marrow of three 20-week-old BALB/cJRj mice. Mice
were sacrificed by cervical dislocation; femurs, and tibias were harvested and kept on ice in PBS-A
(without Mg2+ and Ca2+). Bone marrow was flushed out from cleaned bones without muscle with
cold PBS-A using a 10 mL syringe and 25-gauge needle into a sterile 50 mL conical tube placed on ice.
Bone marrow cells were centrifuged for 10 min at 4 ◦C and 300 g, the pellet was resuspended in 500
µL of ice-cold PBS-A. Five ml of Gey buffer was added drop by drop to the cell suspension to lyse
contaminating red blood cells. After 10 min of incubation at 4 ◦C, volume was completed to 50 mL
with cold PBS-A and the cell suspension centrifuged for 10 min at 4 ◦C and 300× g. The cell pellet
was carefully resuspended in 1 mL of complete medium to dissociate aggregates. The cell suspension
was diluted in complete medium before cell counting using Malassez microscopy counting slides.
Suspensions of 1.5 × 106 cells/mL were cultivated at 37 ◦C with 7.5% of CO2 in Petri dishes (Petri
Greiner ref: 664161) using complete DMEM medium (Pan DMEM (Biotech P04-03588) with 15% FCS
and 4.5 g/L glucose, 50 µg/mL penicillin and streptomycin, 10 mM HEPES, 50 µM β-ME) supplemented
with 50 ng/mL M-CSF-1 (rm M-CSF-1, ref 12343115, ImmunoTools, Friesoythe, Germany). A fresh
medium was added after three days of culture. At day six, supernatants were discarded into Falcon
tubes, and adherent macrophages were harvested by gentle flushing following a 30 min incubation at
37 ◦C in PBS-A containing 25 mM EDTA. Individual cell suspensions (1 for each of 3 mice) were then
transferred to 12-well plates by using 10 mL of PBS-A at 2 × 106 cells/wells. Four culture conditions
were tested for 24 h in complete medium: With or without IrSPI (10 µg/mL), and with or without
stimulation cocktail (0.5 µg/mL LPS and 100 U/mL IFN-γ). Respective controls were complete medium
or complete medium with stimulation cocktail.
2.10.13. Cytokine Profile Analysis
The impact of IrSPI on cytokine production was evaluated in splenocytes (with or without ConA
stimulation) and in LPS and IFN-γ-activated macrophages with the Luminex Procarta PPX-01-S26088EX
kit (Invitrogen) targeting mouse Th1 (IL2, IL-1β, IFN-γ, TNFα, IL12p70, IL-18), Th2 (IL4, IL5, IL6,
IL-10, IL-13, IL9), Th17 (IL-17, IL-23, IL-27), and Th22 (IL-22) cytokines, chemokines (Eotaxin, Groα-KC,
IP10, MIP-1α, MIP-1β, MIP2, MCP1, MCP3, RANTES), and one colony-stimulating factor (GM-CSF),
according to the manufacturers’ instructions. Supernatant (50 µL) from splenocytes cultured with or
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without mitogen stimulation, and with or without IrSPI, and 100 µL of supernatant from activated
macrophages cultivated with or without IrSPI, as described above, were used. Each supernatant
was incubated for 1.5 h with magnetic beads coated with antibodies directed against the targeted
cytokines. The beads with immobilized cytokines were then successively incubated with biotinylated
anti-cytokine antibodies and streptavidin-PE, and analyzed using the LuminexTM 200 system (Bio-Rad,
Hercules, CA, USA).
2.10.14. Statistical Analysis
GraphPad Prism version 7.8 was used to perform ANCOVA test for inhibition assay linear
regression analysis, Student’s t-test to evaluate the significance of IrSPI expression and angiogenesis
parameters, as well as splenocyte proliferation differences in response to IrSPI exposure. p-values <
0.05 were considered as significant (labeled with *), whereas, more significant results with p-values <
0.01 were indicated with **.
Cytokine/chemokine Luminex expression analysis was performed for each of the three mice in
triplicate, and in duplicate for splenocytes and macrophages. ANOVA analysis was used to evaluate
the variability between triplicates or duplicates and between mice for each measured molecule, with
and without stimulation. The variable “presence or absence of IrSPI” and the variable mouse were
used as a fixed and random effect, respectively. The influence of the protein on the variable “cell
response” was expressed as p values (p < 0.01).
2.10.15. Software
NetNGlyc 1.0 and NetPhos 3.1 servers (DTU Bioinformatics, Lyngby, Denmark) and Phyre 2
software [25] were used in order to predict post-translational modifications and secondary structures
of IrSPI, respectively.
3. Results
3.1. IrSPI Molecular Characterization
The full-length IrSPI cDNA encompasses a 342-nucleotide open reading frame encoding a
19-residue signal peptide, followed by a 285-nucleotide sequence encoding a mature 94 amino acid
protein. I. ricinus and I. scapularis sequences show the highest degree of IrSPI identity (Figure 1A).
The IrSPI sequence harbours seven cysteines which potentially form three disulfide bonds. As in
mammalians, the Kunitz type 1 inhibitors of ticks typically harbor six cysteines, namely, C5, C14, C30,
C38 C51 and C55 (according to the original Kunitz numbering system). These cysteines are involved in
three intra molecular disulfide bonds: C5-C55, C14-C38 and C30-C51. However, several Kunitz-type
inhibitors, including IrSPI, possess an additional cysteine residue, adjacent to the universally conserved
C51 (Figure 1B). In these Kunitz, despite additional cysteine residue, the intra molecular disulfide bond
pattern for the topologically equivalent cysteines is conserved. The extra cysteine following C51 is
unengaged in intra-molecularly bond [26,27]. The putative mature protein has a molecular mass of 8310
Da, a single potential N-glycosylation site, and ten putative phosphorylation sites (Figure 1B). The intact
molecular mass of the recombinant IrSPI expressed in Drosophila S2 cells was analyzed by mass
spectrometry, using the UltrafleXtreme MALDI-TOF/TOF instrument (Bruker-Daltonics, Germany).
Results revealed a 990 Da shift between the experimental mass (13,034 Da) and the theoretical mass
(12,044 Da) of the recombinant protein, which is compatible with the addition of ten phosphoryl
groups (80 Da) and a single N-linked glycan (161 Da) as previously hypothesized via NetNGlyc 1.0
and NetPhos 3.1 servers (Figure S1).
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The predicted protein structure, as determined via Phyre 2 software, consists of two β-sheets, two
α-helices, and a single Kunitz-like inhibitory domain, suggesting that IrSPI belongs to the Kunitz type
I protease inhibitor family (Figure 1C). Recombinant IrSPI protein was used to confirm this structure,
but circular dichroism experiments failed to reveal the expected α-helix signals (Figure S2). In addition,
the main population observed via analytical ultracentrifugation had a sedimentation coefficient of 1.6S
and a frictional ratio (f/f0) of 1.2, consistent with a monomeric and globular form of IrSPI (Figure S3).
The absence of helices in the recombinant IrSPI structure may prevent disulfide bond formation,
consequently causing hydrophobic residues to be exposed at the protein surface. Thus, the globular
aspect of IrSPI could be due to an abortive folding process, and its globular form might represent a
folding intermediary and not the correct functional IrSPI structure. Altogether, results suggest that the
recombinant protein may be misfolded, which might compromise its functional activity as a protease
inhibitor. Consequently, serine protease inhibition assays were performed with a refolded form of
recombinant IrSPI, and the refolding buffer was used as a control.
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3.2. Serine Protease Inhibition
Since the P1 residue of IrSPI is an alanine, we hypothesized that it could inhibit serine proteases
of the elastase-like family. We thus, assessed the ability of IrSPI to inhibit cleavage of the respective
substrates of several serine proteases, including elastase. Although the non-refolded recombinant
protein did not inhibit any serine protease; refolded IrSPI in excess (1 µM) moderately, but significantly
decreased elastase catalytic activity (23.9%; ANCOVA test, p = 0.0002), and that of chymotrypsin very
slightly (1.7%) (Figure 2). Trypsin, thrombin, and kallikrein were not inhibited.
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Figure 2. Inhibition of serine proteases by IrSPI. The ability of IrSPI (1µM of refolded protein in
the refolding buffer) to inhibit the activity of elastase (Elast), trypsin (Tryp), chymotrypsin (Chtryp),
thrombin (Throm), and kallikrein (Kalli) on synthetic substrates was evaluated at 37 ◦C for 30 min.
Enzyme activity was evaluated from the slope of A405 versus time and results were expressed as
the mean of IrSPI-induced percentage inhibition after subtraction of the refolding buffer effect and
comparison with the control. Double asterisks (**) indicate significant results as determined via
ANCOVA analysis (p < 0.001).
3.3. IrSPI Expression and Localisation
To explore IrSPI function, we analyzed its expression by quantitative RT-PCR in all tick stages
from our pathogen-free I. ricinus colony. IrSPI mRNA was not detected in eggs, unfed larvae, nymphs,
adults of either sex or in fed larvae on days 1 and 3 of engorgement. However, comparison of transcript
abundance in unfed, 3-day fed, and 5-day fully engorged nymphs revealed significant upregulation of
IrSPI mRNA following five days of feeding (Figure 3A). IrSPI mRNA expression was then evaluated
in different tissues in a pool of 17 field-collected females pre-fed for five days on a rabbit that was
shown to be infected with Babesia venatorum and Rickettsia helvetica by PCR as previously described [8].
Results showed that in adults, and at roughly halfway through feeding, IrSPI is expressed in SG, guts,
synganglion, ovaries and the rest of tick bodies (carcasses), with significantly higher expression in
SG (Figure 3B). IrSPI-specific transcripts were then analyzed in various organs of B. henselae-infected
I. ricinus. Results confirmed overexpression in SG following infection, and also revealed upregulation
in the gut, and in ovaries to a lesser extent (Figure 3C). Such overexpression was not found following
infection with B. birtlesii, a phylogenetically proximal bacterium.
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Figure 3. IrSPI transcript profiling and localization. (A) Relative IrSPI expression in pathogen-free
nymphs fed on rabbits revealing the delayed gene expression on day 5. At each feeding time point (Days
0, 3, and 5), 20 pathogen-free nymphs were used, and IrSPI expression was assessed by quantitative
RT-PCR relative to the rps4 gene. (B) Relative IrSPI expression in several organs of wild female ticks
pre-fed for five days on the rabbit. Pools of salivary glands (SG), gut (G), synganglion (Syn), ovaries
(Ov), and the remaining body, i.e., the carcasses (car) from 17 females were used for each condition,
and IrSPI expression was assessed by quantitative RT-PCR according to the copy number of IrSPI
plasmid clones. (C) Relative expression of IrSPI in pools of 13 salivary glands (SG), 14 guts (G), and 16
ovaries (Ov) from B. henselae-infected females pre-fed for four days assessed by quantitative RT-PCR,
compared with uninfected samples, and expressed as a fold change with respect to the rps4 gene. (D)
Relative IrSPI and defensin6 expression after E. coli injection. Three pathogen-free females per group
either received no injection (Control), 250 nl of PBS (PBS), or 250 nl of 107 bacterial CFU (E. coli). After
24 h incubation, quantitative RT-PCR was used to assess the mean expression of IrSPI and defensin
6 normalized to rps4. (E) In situ hybridization of IrSPI mRNA in salivary glands of pathogen-free
females pre-fed for eight days on the membrane. A specific IrSPI anti-sense probe was incubated on
salivary glands and visualized through the addition of NBT/BCIP. Arrows indicate the presence of IrSPI
transcripts in cells containing secretory vesicles in type II acini. An IrSPI sense probe was used as a
negative control. Fields 1 to 3 are successive zooms. The scale bars are 60 µm. One asterisk (*) indicate
significant (p < 0.05) and two asterisks (**) highly significant (p < 0.01) differences as determined by
Student’s t-test.
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IrSPI expression was also analyzed after infecting ticks with a non-transmitted bacterium,
Escherichia coli, to evaluate the protein’s potential implication in tick innate immune responses.
The efficiency of this response was validated in parallel by evaluating the expression of defensin6,
which is known to be upregulated in ticks following E. coli infection [16]. While we confirmed that
defensin6 was upregulated following infection, expression of IrSPI remained unchanged (Figure 3D).
To document IrSPI expression in the salivary glands and to determine whether the gene product
is present in tick saliva injected into the vertebrate host, IrSPI mRNAs were analyzed by in situ
hybridization in salivary glands of pathogen-free, partially-fed females. The IrSPI transcript was
identified in the secretion vesicles of type II acini, which are responsible for saliva secretion in hard
ticks [28] (Figure 3E).
The presence of IrSPI protein was then evaluated in both tick saliva and in salivary gland extracts
obtained from a pool of 17 I. ricinus females collected from the field, then pre-fed on a rabbit for five
days. SDS-PAGE analysis revealed major differences in the protein composition of saliva and salivary
gland extracts, with higher total protein observed in salivary glands (Figure 4A). The presence of IrSPI
was confirmed by western blot analysis using antiserum from mice immunized with recombinant
IrSPI (Figure 4B), as well as serum collected from an experimentally tick-infested rabbit (Figure 4C).
Native IrSPI was only faintly detected by the mouse antiserum in tick salivary glands, and not at all
in saliva (Figure 4B). However, the recombinant counterpart was detected, although weakly, by the
serum from a tick-infested rabbit, demonstrating that IrSPI generates an antibody response in rabbits,
and is indeed injected into the host by ticks via the saliva during blood-feeding (Figure 4C). These
results suggest possible differences regarding immunogenicity/conformation and/or protein quantity
between the recombinant and the native proteins, since mouse antiserum recognized lower levels of
native versus recombinant IrSPI.
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recombinan IrSPI (R) were l aded. (A) SDS-PAGE lectrophoresis and UV visualization. (B) We t rn
blot analysis using tiserum from an IrSPI-immunized mouse. (C) Western blo nalysis using an
antiserum from a tick-infested abbit. Bands corresponding to IrSPI are framed with boxes.
3.4. Anticoagulant Activity
Thrombin generation and clot waveform assays were used to test whether IrSPI displays
anticoagulant activity. Thrombin formation was triggered by adding calcium to a premix of plasma,
phospholipid vesicles, and tissue factor, in the presence or absence of varying amounts of ‘refolded’
IrSPI. The kinetic analysis suggested that IrSPI had little or no impact on clot formation (Figure 5).
At concentrations of up to 0.8 µM IrSPI, clot formation lag-time and amounts of thrombin formed
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were comparable between the positive control (peak at 371 s) and samples containing IrSPI (peak at
371 s) or refolding buffer alone (peak at 357 s, Figure 5A). IrSPI also had no significant impact on
fibrin formation, with respective clotting-times of 105 s for controls (with or without refolding buffer)
versus 119 s for samples containing IrSPI (Figure 5B). IrSPI’s clot lysing ability was also investigated
to evaluate its effect on clot stability. Fibrin formation was triggered as above—with a mixture of
phospholipid vesicles, tissue factor, and calcium, but in the presence of tissue plasminogen activator
(tPA) to induce fibrin clot lysis. Again, there was no significant difference between half-lysis times
using refolding buffer with or without IrSPI (279 versus 297 s, respectively; Figure 5C).Vaccines 2019, 7, x  15 of 28 
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3.5. Apoptosis and Angiogenesis
As IrSPI is known to be a component of tick saliva, which precludes tissue remodeling and
angiogenesis, we next hypothesized that it could modulate the formation of new vessels by promoting
apoptosis and/or by inhibiting microvascular endothelial cell proliferation. The ability of refolded
or misfolded recombinant IrSPI to induce apoptosis in comparison with cognate media controls was
first evaluated in HSkMEC endothelial cells by flow cytometry cell viability and apoptosis markers,
i.e., cells labeled with Annexin V-FITC, but not propidium iodide corresponded to apoptotic cells
(Figure 6). Adding 1 µM IrSPI (refolded or not) to culture medium had only a weak effect (11.9% and
9.2% apoptotic cells versus 10.5% with culture medium alone); the greatest effect was actually obtained
by the addition of refolding buffer without IrSPI (25.5%).Vaccines 2019, 7, x  16 of 28 
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endothelial cell lines (Figure 7). In both cell lines, both concentrations of refolded IrSPI reduced several
angiogenesis parameters, but this effect was mainly due to the refolding buffer and not IrSPI itself
(Figure 7).
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Figure 7. Impact of IrSPI on angiogenesis. (A) HEPC-CB1 (human endothelial progenitor cells-cord
blood 1) and (B) HSkMEC endothelial cells were cultivated with IrSPI prior to (IrSPI), or after a
refolding step (IrSPI Ref) for 9.5 h, and the nu ber of junctions, aster junctions, segments, master
segments, meshes, and total segment lengths were recorded via video-microscopy every 30 min and
analyzed with ImageJ software. Results are expressed as means of triplicates. Controls correspond to
culture ediu (ctrl) f l i ff r ( ef buffer). Asterisks (*) indicate significant differ nces as
det rmined using the Student’s t test (p < 0. 5).
3.6. Splenocyte Proliferation Assay
Next, we evaluated whether IrSPI might play a role in host immunomodulation during tick
feeding. Splenocytes isolated from three OF1 mice were cultured in the presence or absence of the
mitogen concanavalin A (ConA) for three days. The impact of non-refolded IrSPI on the proliferation
of three lymphocyte subsets (CD4+ and CD8+ T cells, B cells) was then evaluated by CFSE dye dilution
assay via flow cytometry. In the absence of IrSPI, mitogen-stimulated T, but not B cells, displayed
robust proliferation, though with some inter-individual variability probably attributable to the use of
outbred mice (Figure 8).
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3.7. Cytokine Expression in Response to IrSPI
In order to gain insight into how IrSPI ight influence i une cells, cytokines and che okines
secreted into the supernatants of itogen-sti ulated or unsti ulated splenocytes ere co pared
using a ultiplex bead-based assay. The 26-plex panel included 17 cytokines representing ultiple
T helper subsets (Th1, Th2, Th9, Th17, Th22, and Treg) and nine che okines. In the absence of
itogen sti ulation, but in the presence of IrSPI, the secretion of several cytokines and che okines
as significantly di inished (p < 0.01), in particular IP10 (−32.8 ), CP3 (−72.3 ), IP-1β (−26 ),
and RA TES (−15.6 ) (Table 1 and Table S1). IrSPI also significantly decreased several chemokines in
mitogen-stimulated splenocytes including IP10 (−46.5%), MIP-1β (−17.9 ), RA TES (−37.9 ) and
Eotaxin (−21.3 ) (p < 0.01). Moreover, expression of several cytokines, na ely, IF -γ (−50.3 ), IL-1β
(−45%), IL-18 (−46%), IL-13 (−75.1%), IL-6 (−54.8%), T F-α (−46,1%), IL-9 (−48.8%), and G -CSF
(−71.9 ) as also significantly reduced (p < 0.01), (Table 1 and Table S2). In contrast, a single cytokine,
IL-2, as significantly upregulated (+49.2 ) follo ing IrSPI exposure.
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Table 1. Impact of IrSPI on murine splenocyte and macrophage cytokine/chemokine production with
or without mitogen stimulation by concanavalin A (ConA).
Conditions Cytokine/Chemokine Effect of IrSPI (Percentage) p-Value
Splenocytes
Without ConA
IP10 −32.8% 2.21 × 10−3
MCP3 −72.3% 8.07 × 10−4
MIP-1β −26.0% 2.11 × 10−3
RANTES −15.6% 3.94 × 10−3
With ConA
IL-1β −45.0% 1.15 × 10−3
IL-13 −75.1% 4.47 × 10−4
IL-18 −46.0% 1.63 × 10−7
IL-6 −54.8% 5.80 × 10−6
IL-9 −48.8% 7.06 × 10−3
TNF-α −46.1% 7.23 × 10−6
IFN-γ −50.3% 2.28 × 10−7
IP10 −46.5% 4.30 × 10−5
MIP-1β −17.6% 2.28 × 10−3
RANTES −37.9% 1.26 × 10−4
Eotaxin −21.3% 3.89 × 10−3
GM-CSF −71.9% 8.67 × 10−8
IL-2 + 49.2% 5.62 × 10−4
Macrophages
With LPS/IFN-γ IL-5 −9.6% 8.37 × 10−3
All results are presented as significant expression changes (p-value < 0.01; ANOVA) after a three-day IrSPI incubation.
Splenocytes from each of three mice were separately evaluated in triplicate for each condition. Results are expressed
as the mean for the three mice after calculating the mean of triplicate wells for each mouse.
To address the impact of IrSPI on sentinel immune cells, we also compared T helper cytokines
and chemokines in the supernatants of IFN-γ-and LPS-activated murine macrophages grown in the
presence or absence of IrSPI. All tested T helper cytokines and chemokines were diminished, but only
the decrease in IL-5 was statistically significant (−9.6%; p < 0.01; Table 1 and Table S3).
Taken together, our data suggest that, apart from IL-2, IrSPI repressed splenocyte—and
macrophage-activated secretion of multiple T helper cytokines and chemokines, consistent with
a role for IrSPI as a modulator of the host immune response against tick bites.
4. Discussion
Further knowledge is continually accumulating regarding the capacity of hard and soft tick
saliva to counteract native host immune responses to enable successful blood meal completion [29–31].
Relatively few salivary compounds, however, have undergone thorough molecular characterization,
or have been identified as the active factors responsible for this process (recently reviewed in [3]).
We previously identified a tick serine protease inhibitor—IrSPI—potentially present in I. ricinus
saliva and likely implicated in tick feeding and in I. ricinus salivary gland infection by Bartonella [5].
The presence of genes homologous/paralogous to IrSPI in both I. ricinus and I. scapularis ticks suggests
that it belongs to a family of SPI proteins that have important physiological functions, with highly
conserved regulatory roles. Here we also provide evidence that IrSPI is a Kunitz SPI that is induced
during blood-feeding and appears to be present in tick saliva, even if this will have to be validated
by proteomic studies. Moreover, we show that IrSPI inhibits elastase and modulates host immune
responses. It is likely that such immunomodulation substantially contributes to successful feeding and
engorgement of I. ricinus ticks, and thereby facilitates TBP transmission.
Production of functionally active recombinant protein is known to be difficult. As an example,
the Dermacentor andersoni p36 immunosuppressive salivary gland protein was only active when the
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recombinant protein was expressed in insect cells, but not in bacteria [32], suggesting that functional
activity might depend upon proper post-translational modifications, such as glycosylation. Similarly,
Konnai and co-workers have tentatively attributed the inability of Ixodes persulcatus lipocalin to bind
histamine to the expression of recombinant protein in E. coli [33]. In the present study, we expressed
IrSPI in Drosophila cells and showed that the protein was functional, e.g., it exerted immunomodulatory
activity. However, circular dichroism analysis of recombinant IrSPI suggested that it lacked important
Kunitz secondary structural features. It is likely that the typical disulfide bonds pattern of kunitz type
1 (C5-C55, C14-C38 and C30-C51) was not well-formed, and thus, the recombinant protein might be
jam in a folding intermediate. That prevents the good exposition of the reactive loop and the inhibition
of serine proteases. Nonetheless, when subjected to a refolding step that consists of reforming good
disulfide bonds intramolecularly thanks to the isomerase activity of PDI, the recombinant protein
displayed inhibitory activity against elastase.
In light of its primary structure, IrSPI belongs to the Kunitz SPI superfamily, whose members
competitively inhibit serine protease activity in a reversible lock-and-key fashion. In ticks, several
members of this superfamily are known to subvert host defense mechanisms during feeding [7].
Invertebrate Kunitz inhibitors possess diverse inhibitory effects on several serine proteases depending
on their amino acid sequence, especially the P1 residue of the reactive site loop. Positively charged Lys
or Arg, as P1 residues are associated with inhibition of trypsin-like serine proteases; large hydrophobic
residues, such as Phe, Tyr, or Leu, with chymotrypsin-like serine proteases; and small hydrophobic
residues, such as Ala or Val, with elastase-like serine proteases [34]. We showed that IrSPI, though
harboring Ala as its P1 residue, does indeed inhibit elastase albeit to a lesser extent than that reported
in the literature for other tick kunitz protease inhibitors [35,36]. IrSPI also inhibited chymotrypsin
activity, albeit weakly, in keeping with the partial fit of an Ala-bearing SPI within the protease active
site, but less effectively than an SPI bearing large hydrophobic amino acids at this P1 position. Elastase,
a serine protease synthesized and released by neutrophil cells following trauma, is responsible for
tissue inflammation and remodeling [37]; chymotrypsin also participates in this latter process [38].
Through its inhibitory activity, IrSPI might, thus, reduce inflammation and inhibit tissue repair
processes following the tick bite, as has been suggested for other Kunitz SPIs, such as Ixodes scapularis
tryptogalinin which also inhibits elastase, among other proteases [39].
We showed that IrSPI mRNA was expressed in various organs from pooled ticks, including SG,
gut, ovaries, and synganglion, as well as the carcasses of wild pre-fed ticks that harbored—for at least
one of the pooled ticks—two TBP. This broad tissue distribution suggests that IrSPI might be implicated
in multiple aspects of tick biology. IrSPI expression in pools containing infected ticks is compatible with
its induction by TBP, as we previously demonstrated for B. henselae [5]. In fact, TBP infection has already
been shown to modulate the expression of many tick genes, and a number of these—including some
encoding Kunitz proteins—have been identified as implicated in TBP transmission [40]. Such molecular
interactions reflect the vector competence of an arthropod [4], and may be TBP-specific, as shown for
IrSPI regarding B. henselae and B. birtlesii. Previous RNAi experiments have also shown that IrSPI
is likely involved in bacterial adhesion, invasion, and/or multiplication within tick salivary glands,
and also potentially in tick defense mechanisms, as it may act against other bacteria in competition
with B. henselae [5]. This latter hypothesis was, thus, evaluated using E. coli, but IrSPI upregulation
was not observed following tick infection with this non-transmitted bacterium.
We next demonstrated that IrSPI expression is induced in tick salivary glands by the blood-feeding
process, both in nymphs at the end of engorgement (day 5) and in females in the middle of the
feeding process, and in the latter context on day 5 on rabbits, and on days 4 and 8 on membrane [5].
The immunomodulatory activity of IrSPI that we observed—that is, reduction in T cell proliferation
and more particularly in proliferation of the CD4+ T subset—is compatible with late expression of
IrSPI, as the T-cell response is only expected to be initiated following the early inflammatory response.
Similar blood-meal induction has also been reported for the Irsgmg-150466 transcript, which likely
corresponds to the IrSPI gene as it has 100% identity at the protein level, but without a signal peptide
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sequence. Irsgmg-150466 expression peaked 12 h after attachment, but then decreased after 24 h
and 12 h in I. ricinus female and nymph salivary glands, respectively [41]. Chmelar and co-workers
reported the expression of a homologous gene (contig 240) in I. ricinus female salivary glands 24 h after
tick attachment [42]. Dynamic expression of IrSPI paralogs was also recently reported by Dai et al.
in I. scapularis [43], lending support to variable BPTI/Kunitz gene expression by both I. ricinus and
I. scapularis during blood meal ingestion, with time-dependent up- or down-regulation. Nevertheless,
it should be noted that in these studies, expression level is only based on mRNA detection, which may
differ from protein expression, as variable transcript expression does not necessarily translate into
variation in expression of the corresponding protein.
The presence of a signal peptide combined with salivary gland transcript expression indicated
that IrSPI was likely to be a secreted protein present in tick saliva. We have shown that IrSPI mRNA is
expressed in type 2 acini, which are responsible for saliva secretion, and using anti-IrSPI antibodies
raised in tick-infested rabbits, that native IrSPI protein may be present in tick saliva and injected into
the host during feeding. This demonstrates that IrSPI takes part in the molecular dialogue between the
tick and its vertebrate host, and strongly argues in favor of a role for IrSPI in the tick feeding process.
Host skin is the first barrier that ticks need to overcome for successful feeding. Upon tissue damage,
host skin cellular components—including epithelial cells, fibroblasts, and endothelial cells—generate
biomolecules that facilitate tissue remodeling and wound healing, such as angiogenesis. In order to
remain attached to their host and capable of obtaining blood over several days, these slow-feeding
hematophagous arthropods must inhibit these processes. The first study demonstrating that tick
saliva inhibits angiogenesis was published in 2005 [30]. Since then, few salivary molecules have been
reported to modulate angiogenesis and wound healing. These include Kunitz SPI from Haemaphysalis
longicornis (Haemangin [44]), R. microplus (BmTI-A [36], and BmCI [45]), and Amblyomma cajennense
(Amblyomin-X [46]). Nevertheless, although IrSPI, like BmTI-A and BmCI, acts as an elastase inhibitor,
it does not seem to exert direct activity on apoptosis of HSkMEC cells, or angiogenesis in HSkMEC
and HEPC-CB [1] cells. It should be noted, however, that this in vitro observation may not hold true
for the whole organism, where suppression of angiogenesis-related proinflammatory cytokines by
IrSPI, as observed in both splenocytes and macrophage cells, might exert an indirect effect.
To initiate blood-feeding, the tick must lacerate the host tissue, which exposes to blood large
quantities of tissue factors triggering activation of the blood coagulation cascade that induces fibrin
clot formation and its subsequent lysis. Blood coagulation is, thus, rapidly triggered following
tick bite-induced blood vessel damage. Several tick factors counteract vertebrate blood hemostasis
(reviewed in [3]), the majority belonging to the SPI family. In fact, most of the tick SPI injected into the
host during blood-feeding facilitate completion of the long blood meal by targeting one or several
serine protease(s) involved in blood coagulation pathways, thereby preventing fibrin clot formation
and maintaining blood in a fluid state at the tick bite site [7]. IrSPI, however, did not appear to
modulate blood coagulation, as no effect was observed on thrombin generation or fibrin formation.
In addition, albeit several tick SPI accelerate lysis of fibrin clot [7], IrSPI failed to demonstrate such
activity. Nevertheless, this result was somehow expected given that the P1 residue of IrSPI is alanine,
suggesting elastase-like targets rather than blood coagulation proteases which are all trypsin-like
enzymes [47]. Further investigations would be required to determine whether IrSPI regulate other
blood coagulation processes, such as platelet aggregation.
To avoid host rejection, ticks have developed a complex armament to circumvent both innate and
adaptive immune responses, as well as complement activation [29]. Relatively few tick salivary factors
responsible for this immunomodulation have been identified (reviewed in [3]). These factors have been
reported to play a role in the activation and/or recruitment of multiple resident and infiltrating cell types
at the tick bite site, including macrophages, mast cells, dendritic cells, endothelial cells, keratinocytes,
and lymphocytes, as well as in the polarization of an initial Th1 helper response towards a Th2
orientation, considered to be more favourable to tick blood-feeding [29]. Here we showed that IrSPI
inhibits mitogen-induced proliferation of murine CD4+ T cells, as has been reported for saliva of not
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only I. ricinus [48], but also several other tick species including D. andersoni [49], A. variegatum [50], and
I. dammini [51]. It is noteworthy that in our study, IrSPI inhibited secretion of IL-9, which promotes the
proliferation of CD4+ rather than CD8+ T cells [52]. Until now, a small number of salivary proteins with
immunosuppressive capacity have been characterized, including Salp15 from I. scapularis [53], the most
highly-investigated protein, P36 from D. andersoni [32], and Iris from I. ricinus [54]. It should be noted
that in our study, the impact of IrSPI was assessed on mouse splenocytes, which comprise, in addition
to the high proportion of T cells, multiple other immune cell types, such as B cells, macrophages,
dendritic cells, eosinophils, basophils, natural killer cells and neutrophils. Thus, indirect actions of
IrSPI on T cells via other cells should not be excluded, as has already been suggested for dendritic
cells [55]. Indeed, we observed that IrSPI decreased splenocyte expression of multiple chemokines
and cytokines that directly or indirectly stimulate T cell proliferation, including MIP-1β, RANTES,
and IL-9 [56,57]. Furthermore, we showed that IrSPI also repressed the expression of IL-13, which is
mainly produced by Th2 lymphocytes, and which may regulate proliferation and differentiation of
DCs and B cells [58].
At the tick bite site, and in response to tissue damage, numerous cell types (including fibroblasts,
endothelial cells, macrophages, DCs, T cells, neutrophils, eosinophils, and resident tissue cells) are
able to secrete immunological factors, thereby promoting inflammation, tissue remodelling, wound
healing, angiogenesis, and pathogen clearance. To repress immune cell activation and proliferation
that, if unchecked, would compromise tick feeding, tick saliva, as a rich source of immune modulators
(reviewed in [3]) acting in concert to achieve a stronger effect, hijacks cellular immune responses and
notably secretion of cytokines and chemokines, thus, affecting the previously mentioned processes.
Our results showed that for I. ricinus, IrSPI, as part of this salivary cocktail, represents one of the
molecules that are likely to contribute to the modification of these molecular profiles, and suggest a
broader function of IrSPI along with tick feeding in vivo due to serine protease inhibitor numerous
roles in mammalian physiology.
Inhibition of proinflammatory molecules by total salivary gland extracts of I. ricinus has already
been reported [59]. Among IrSPI down-regulated molecules, MIP-1β, GM-CSF, and RANTES—strongly
associated with secretion of IFN-γ—are considered to be proinflammatory factors typically expressed
in response to infection, promoting the recruitment of effector cells to the site of pathogen entry [60].
Our data also showed that IrSPI decreased the expression of IFNγ as has been reported for salivary gland
extracts of I. ricinus [61]. IFNγ is principally produced by cytotoxic and Th1 cells, and constitutes one
of the primary regulators of both innate and adaptive immunity, as well as inflammation. Local tissue
inflammation and allergic reactions at the tick bite site are also controlled by IrSPI through the inhibition
of eotaxin-1, IL-18, or IL-9. Inhibition of this last cytokine has also been reported for the salivary cysteine
protease inhibitor sialostatin L from I. scapularis, thus, preventing the development of experimental
asthma [62].
In addition, and like the dendritic cell modulator Japanin from Rhipicephalus appendiculatus [63],
IrSPI also repressed the expression of TNFα, which is predominantly produced by both activated
macrophages and T lymphocytes in inflammatory and infectious conditions. Although unable to
drive the differentiation of naïve CD4+ cells towards a Th2 phenotype in a direct manner, IL-13, also
repressed by IrSPI, may affect T cell function indirectly via downregulation of proinflammatory Th1
cytokines, including IL-12, which have been shown to be also repressed by OmC2 from the soft tick
Ornithodoros moubata [64].
Like Japanin [63], IrSPI decreased IL-1β. In addition to triggering the release of other
proinflammatory cytokines, this cytokine—which is secreted following injury—activates neutrophil
and macrophage phagocytosis and the release of toxic oxygen and nitrogen radicals. As serine proteases
from neutrophils and macrophages, such as elastase, have been reported to process pro-IL-1β into
active fragments [65], we, thus, cannot exclude a role for IrSPI as an indirect inhibitor of IL-1β secretion
through inhibition of these molecules. As this cytokine was among the most highly downregulated
in the presence of IrSPI, and given the importance of IL-1β in both immune cell recruitment and
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nociception, its suppression by IrSPI may well participate in avoidance of tick rejection by the host.
Besides IL-1β pain sensation is reinforced by the release of pro nociceptive chemokines and cytokines,
including TNFα, IFNγ, IL-6, IL-18, MCP3, RANTES, and MIP-1β, at the tick bite site [66], and these
are also repressed by IrSPI in cultured splenocytes. Immune cell recruitment might also be impacted
by IrSPI through the modulation of MIP-1β, RANTES, GM-CSF, and IP10 or IL-6, triggering the
expression of T cell attractant chemokines and eotaxin-1, TNF-α, or IL-13 which regulate cell adhesion
proteins [67].
As ticks must maintain blood flow at the bite site in order to feed successfully, inhibition of
several cytokines/chemokines by IrSPI might antagonize host homeostasis and angiogenesis. Affected
cytokines include RANTES, which modulates neovascularization, endothelial cell migration and
spreading [68], IL-6, which induces VEGF [69], TNF which stimulates COX 2 [70], and eotaxin-1 which
affects endothelial cell chemotaxis and in vivo blood vessel formation [71].
The immunosuppressive effect of IrSPI on the host will naturally also influence the transmission
of tick-borne pathogens. Several of the cytokines/chemokines repressed by IrSPI, including RANTES,
MIP-1β, IL-18 and IL-9, are also implicated in pathogen control and clearance mechanisms, including
effector cell recruitment to the pathogen entry site [60,72]. While IrSPI significantly inhibits most
proinflammatory cytokines and chemokines, a single cytokine, IL-2, was upregulated. This result
was somewhat unexpected in the light of published data reporting decreased IL-2 expression by tick
saliva [29]. Nevertheless, while IL-2 is often considered to be proinflammatory, it can also behave as
an anti-inflammatory cytokine by promoting differentiation of Treg cells, as well as their long-term
survival, and suppressive activities [73], thereby decreasing local inflammation and promoting
pathogen tolerance [74].
Together with the splenocyte results, the macrophage response to IrSPI confirms that this salivary
molecule downregulates both proinflammatory and Th1-promoting cytokines. A similar result has
been reported where TNF-α, IL-12, and IFN-γwere decreased in LPS-activated bovine macrophages
exposed to R. microplus saliva [75]. While all tested cytokines decreased in this study, only IL-5 from
mouse macrophages was significantly lowered. This cytokine is reported to have proinflammatory
functions, including eosinophil activation, B cell growth, and the stimulation of antibody production.
Its proinflammatory features are reinforced via its ability to increase the susceptibility of B and T cells
to IL-2, and subsequently the production of cytotoxic T cells. Although this cytokine is predominantly
expressed by CD4+ T cells, recent evidence suggests that macrophages may also produce IL-5 [76].
5. Conclusions
IrSPI is produced by the most common tick vector in Europe and seems to be a vital component
of the tick salivary cocktail that enables the tick to overcome the host immune system’s defenses
to feed successfully and transmit pathogens. While further investigations are required to gain a
full understanding of the molecular processes that modulate the host immune response, this work
represents a significant advance in the characterization of key immunomodulatory molecules in tick
saliva. IrSPI also represents a potential target antigen for anti-tick vaccine development, as host immune
responses elicited against such immunomodulatory tick molecules may diminish tick infestation and/or
TBD transmission. Anti-tick vaccines hold the promise of affording broad protection against multiple
TBD transmitted by the same vector. The utilization of “exposed” salivary antigens, such as IrSPI,
rather than “concealed” tick antigens to which the host is never naturally exposed, may enable the
host response to be naturally boosted upon exposure to ticks [77]. Also, immunity against such
proteins may block the feeding process prior to pathogen transmission, which typically occurs many
hours or even days after tick attachment. Finally, and although we have reported an impact of IrSPI
silencing on both tick feeding and bacteria transmission, IrSPI belongs to a protein family with extensive
functional redundancy [78]. In consequence, the vaccinal potential of IrSPI would likely be evaluated by
promoting immune responses against epitopes that are common to the IrSPI protein family. Moreover,
the protection afforded by IrSPI should ideally be assessed in the context of multivalent anti-tick
Vaccines 2019, 7, 148 24 of 28
vaccines comprising a cocktail of salivary antigens involved in distinct mechanisms that counteract
host defenses by different mechanisms. Furthermore, due to its immunomodulatory activities, IrSPI
may also represent a potential candidate as a therapeutic molecule in pathologies linked to immune
cell proliferation disorders.
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